Similar to ALL models, AML PDX models have been used to study targeted therapies, including FLT3 inhibitors in FLT3/ITD AML PDX models and menin inhibitors in KMT2A-rearrangement (KMT2A-r) AML51,56,57. Here, MEN1 is linked to acute myeloid leukemia.